Francesco Latrofa

List of Publications by Year
in descending order

61	2,713	159358	182168
papers	citations	30 h-index	51 g-index

66	66	66	2306
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade. European Thyroid Journal, 2022, 11, .	1.2	2
2	Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis. European Thyroid Journal, 2021, 10, 237-247.	1.2	7
3	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, bvab093.	0.1	3
4	Subacute Thyroiditis During the SARS-CoV-2 Pandemic. Journal of the Endocrine Society, 2021, 5, bvab130.	0.1	25
5	Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3742-e3746.	1.8	132
6	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2845-e2852.	1.8	7
7	Subacute Thyroiditis After Sars-COV-2 Infection. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2367-2370.	1.8	283
8	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1581-1588.	1.8	27
9	The Detection of Serum IgMs to Thyroglobulin in Subacute Thyroiditis Suggests a Protective Role of IgMs in Thyroid Autoimmunity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2261-e2270.	1.8	20
10	Patients with chronic autoimmune thyroiditis are not at higher risk for developing clinically overt thyroid cancer: a 10-year follow-up study. European Journal of Endocrinology, 2020, 183, 317-323.	1.9	9
11	Gravesâ€™ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. European Thyroid Journal, 2019, 8, 192-195.	1.2	49
12	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2520-2526.	1.8	15
13	The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors. Scientific Reports, 2019, 9, 4390.	1.6	12
14	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. Frontiers in Oncology, 2019, 9, 1390.	1.3	3
15	Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.2	35
16	A patient with MEN1 and endâ€‘stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. Molecular and Clinical Oncology, 2018, 8, 449-452.	0.4	0
17	Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. JAMA Ophthalmology, 2018, 136, 613.	1.4	52
18	Effect of Thyroglobulin Autoantibodies on the Metabolic Clearance of Serum Thyroglobulin. Thyroid, 2018, 28, 288-294.	2.4	18

#	Article	IF	Citations
19	Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Gravesâ€™ disease. Autoimmunity Highlights, 2018, 9, 3.	3.9	18
20	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. Frontiers in Endocrinology, 2018, 9, 590.	1.5	5
21	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without¹³¹I Ablation. Thyroid, 2018, 28, 871-879.	2.4	35
22	Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?. Frontiers in Endocrinology, 2018, 9, 314.	1.5	66
23	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. Thyroid, 2018, 28, 1318-1324.	2.4	6
24	Does Gravesâ€™ Orbitopathy Ever Disappear Answers to an Old Question. European Thyroid Journal, 2017, 6, 263-270.	1.2	16
25	Low Elasticity of Thyroid Nodules on Ultrasound Elastography Is Correlated with Malignancy, Degree of Fibrosis, and High Expression of Galectin-3 and Fibronectin-1. Thyroid, 2017, 27, 103-110.	2.4	34
26	Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Gravesâ€™ Orbitopathy. Thyroid, 2017, 27, 271-278.	2.4	53
27	Variables Affecting the Long-Term Outcome of Graves Orbitopathy Following High-Dose Intravenous Glucocorticoid Pulse Therapy in Patients not Treated with Orbital Radiotherapy. Endocrine Practice, 2016, 22, 1177-1186.	1.1	9
28	Significance of Low Levels of Thyroglobulin Autoantibodies Associated with Undetectable Thyroglobulin After Thyroidectomy for Differentiated Thyroid Carcinoma. Thyroid, 2016, 26, 798-806.	2.4	32
29	Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study. European Journal of Endocrinology, 2015, 172, 269-276.	1.9	48
30	Role of the Underlying Thyroid Disease on the Phenotype of Graves' Orbitopathy in a Tertiary Referral Center. Thyroid, 2015, 25, 347-351.	2.4	38
31	Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy. Thyroid, 2015, 25, 846-850.	2.4	32
32	Iodine, Thyroid Autoimmunity and Cancer. European Thyroid Journal, 2015, 4, 26-35.	1.2	38
33	Optic Neuropathy in 2 Thyroidectomized Patients with Moderate to Severe Graves Ophthalmopathy Following L-Thyroxine Withdrawal Prior to Radioiodine Treatment for Thyroid Carcinoma. AACE Clinical Case Reports, 2015, 1, e119-e122.	0.4	4
34	Over Hypothyroidism in a Woman Undergoing Controlled Ovarian Hyperstimulation. Endocrine Practice, 2014, 20, e11-e13.	1.1	3
35	The Large Majority of 1520 Patients With Indeterminate Thyroid Nodule at Cytology Have a Favorable Outcome, and a Clinical Risk Score Has a High Negative Predictive Value for a More Cumbersome Cancer Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3700-3707.	1.8	47
36	Spontaneous Improvement of Untreated Mild Graves' Ophthalmopathy: Rundle's Curve Revisited. Thyroid, 2014, 24, 60-66.	2.4	88

#	Article	IF	Citations
37	An update on the medical treatment of Gravesâ€™ hyperthyroidism. Journal of Endocrinological Investigation, 2014, 37, 1041-1048.	1.8	31
38	Enalapril Reduces Proliferation and Hyaluronic Acid Release in Orbital Fibroblasts. Thyroid, 2013, 23, 92-96.	2.4	21
39	Iodine Contributes to Thyroid Autoimmunity in Humans by Unmasking a Cryptic Epitope on Thyroglobulin. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1768-E1774.	1.8	62
40	Thyroid Volume and Severity of Graves' Orbitopathy. Thyroid, 2013, 23, 97-102.	2.4	20
41	Thyroglobulin Autoantibodies in Patients with Papillary Thyroid Carcinoma: Comparison of Different Assays and Evaluation of Causes of Discrepancies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3974-3982.	1.8	47
42	Outcome of Graves' Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E44-E48.	1.8	62
43	Lymphocytic Thyroiditis on Histology Correlates with Serum Thyroglobulin Autoantibodies in Patients with Papillary Thyroid Carcinoma: Impact on Detection of Serum Thyroglobulin. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2380-2387.	1.8	61
44	Diffuse and Nodular Goiter. , 2012, , 9-48.		2
45	Rehabilitative Orbital Decompression for Graves' Orbitopathy: Risk Factors Influencing the New Onset of Diplopia in Primary Gaze, Outcome, and Patients' Satisfaction. Thyroid, 2012, 22, 1170-1175.	2.4	46
46	Characterization of thyroglobulin epitopes in Sardinian adults and juveniles with Hashimotoâ€™s thyroiditis: evidence against a major effect of age and genetic background on Bâ€cell epitopes. Clinical Endocrinology, 2010, 73, 110-113.	1.2	18
47	Evidence that Shed Thyrotropin Receptor A Subunits Drive Affinity Maturation of Autoantibodies Causing Gravesâ€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 927-935.	1.8	47
48	Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 591-596.	1.8	74
49	Autoimmune Hypothyroidism. , 2007, , 137-176.		4
50	Human Monoclonal Thyroglobulin Autoantibodies: Epitopes and Immunoglobulin Genes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5116-5123.	1.8	25
51	Thyroid Stimulation Does Not Require Antibodies with Identical Epitopes But Does Involve Recognition of a Critical Conformation at the N Terminus of the Thyrotropin Receptor A-Subunit. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1788-1793.	1.8	18
52	Affinity-Enrichment of Thyrotropin Receptor Autoantibodies from Gravesâ€™ Patients and Normal Individuals Provides Insight into Their Properties and Possible Origin from Natural Antibodies. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4734-4745.	1.8	41
53	Evidence That the Thyrotropin Receptor Protease is Membrane-Associated and is Not Within Lipid Rafts. Thyroid, 2004, 14, 801-805.	2.4	9
54	Thyroglobulin-Thyroperoxidase Autoantibodies Are Polyreactive, Not Bispecific: Analysis Using Human Monoclonal Autoantibodies. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 371-378.	1.8	30

#	Article	IF	Citations
55	Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens. Annals of Internal Medicine, 2003, 139, 346.	2.0	307
56	The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. Journal of Clinical Investigation, 2003, 111, 1897-1904.	3.9	130
57	The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. Journal of Clinical Investigation, 2003, 111, 1897-1904.	3.9	178
58	Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. Journal of Clinical Investigation, 2002, 110, 209-217.	3.9	95
59	Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. Journal of Clinical Investigation, 2002, 110, 209-217.	3.9	75
60	Circulating Thyroglobulin Transcytosed by Thyroid Cells Is Complexed with Secretory Components of Its Endocytic Receptor Megalin*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3458-3467.	1.8	18
61	Serum Antibodies against Megalin (GP330) in Patients with Autoimmune Thyroiditis1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2468-2474.	1.8	20